Table 1.
The clinical characteristics of the participants.
| CON (n = 34) |
HTN (n = 45) |
HTH (n = 18) |
P value | |
|---|---|---|---|---|
| Age (years) | 29.6 ± 0.6 | 34.6 ± 1.0∗ | 36.3 ± 2.1∗# | 0.0003 |
| BMI (kg/m2) | 21.4 ± 0.6 | 22.2 ± 0.5 | 23.7 ± 0.9 | 0.0674 |
| Course (months) | 0 | 13.6 ± 2.7∗ | 29.7 ± 10.7∗ | 0.0001 |
| Levothyroxine use (n, %) | 0 | 13 (30%) | 13 (72%) | 0.0001 |
| TT3 (ng/mL) | 1.1 ± 0.02 | 1.01 ± 0.02 | 1.10 ± 0.05 | 0.0812 |
| TT4 (µg/dL) | 7.37 ± 0.24 | 7.15 ± 0.16 | 6.36 ± 0.26∗ | 0.0169 |
| FT3 (pg/mL) | 2.91 ± 0.06 | 2.94 ± 0.05 | 3.08 ± 0.07 | 0.2013 |
| FT4 (ng/dL) | 1.23 ± 0.03 | 1.26 ± 0.03 | 1.06 ± 0.05∗# | 0.0002 |
| TSH (µIU/mL) | 1.87 ± 0.16 | 2.19 ± 0.12 | 12.70 ± 4.66∗# | 0.0001 |
| A-TG > 115U/mL (n/total) | 0/31 | 41/43 | 11/14 | <0.0001 |
| A-TPO > 34 U/mL (n/total) | 0/33 | 28/43 | 9/14 | <0.0001 |
Data are shown as mean ± SEM or number (%). CON, healthy controls; HTN, patients bearing Hashimoto's thyroiditis with euthyroidism; HTH, HT patients with hypothyroidism; BMI, body mass index; TT3, total triiodothyronine; TT4, total thyroxine; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone; A-TG, thyroglobulin antibody; A-TPO, thyroperoxidase antibody. ∗Significant difference compared to the CON group. # Significant difference compared with the HTN group.